We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+59.91%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$255M
AUM Growth
-$103M
Cap. Flow
-$140M
Cap. Flow %
-54.73%
Top 10 Hldgs %
45.35%
Holding
89
New
26
Increased
17
Reduced
12
Closed
26

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$7.51M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$6.07M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$3.74M
4
MORF
Morphic Holding, Inc. Common Stock
MORF
+$3.67M
5
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$3.24M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$12.9M
2
SNY icon
Sanofi
SNY
+$11.4M
3
ESTA icon
Establishment Labs
ESTA
+$8.21M
4
KURA icon
Kura Oncology
KURA
+$5.92M
5
AZN icon
AstraZeneca
AZN
+$5.64M

Sector Composition

Rank Sector Weight
1 Healthcare 81.4%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
51
DELISTED
Seagen Inc. Common Stock
SGEN
$643K 0.25%
+5,000
New +$645K
CNTX icon
52
Context Therapeutics
CNTX
$56.6M
$584K 0.23%
883,654
– –
INZY
53
DELISTED
Inozyme Pharma
INZY
$525K 0.21%
+500,000
New +$874K
NUVB icon
54
Nuvation Bio
NUVB
$2.18B
$480K 0.19%
+250,000
New +$506K
IMTXW
55
DELISTED
Immatics N.V. Warrants
IMTXW
$470K 0.18%
187,204
– –
MIST icon
56
Milestone Pharmaceuticals
MIST
$147M
$396K 0.16%
+100,000
New +$526K
SCLXW icon
57
Scilex Holding Co Warrant
SCLXW
$2.77M
$3.42K ﹤0.01%
18,099
-81,901
-82% -$17.9K
MSACW
58
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$2.93K ﹤0.01%
33,333
– –
SCLX icon
59
Scilex Holding
SCLX
$53.7M
$1.85K ﹤0.01%
+13
New +$3.21K
ACRS icon
60
Aclaris Therapeutics
ACRS
$778M
– –
-136,434
Closed -$2.15M
AZN icon
61
PUT
AstraZeneca
AZN
$255B
– –
-50,000
Closed -$5.48M
FXB icon
62
PUT
Invesco CurrencyShares British Pound Sterling Trust
FXB
$77.5M
– –
-10,000
Closed -$1.07M
FXE icon
63
PUT
Invesco CurrencyShares Euro Currency Trust
FXE
$332M
– –
-20,000
Closed -$1.81M
GSK icon
64
GSK
GSK
$100B
– –
-75,000
Closed -$2.21M
GSK icon
65
PUT
GSK
GSK
$100B
– –
-110,000
Closed -$3.24M
IWM icon
66
PUT
iShares Russell 2000 ETF
IWM
$81.2B
– –
-70,000
Closed -$11.5M
KURA icon
67
PUT
Kura Oncology
KURA
$948M
– –
-37,100
Closed -$507K
LNTH icon
68
PUT
Lantheus
LNTH
$6.8B
– –
-30,000
Closed -$2.11M
MDGL icon
69
PUT
Madrigal Pharmaceuticals
MDGL
$12.4B
– –
-75,000
Closed -$4.87M
MIST icon
70
CALL
Milestone Pharmaceuticals
MIST
$147M
– –
-137,200
Closed -$1.26M
NAUT icon
71
Nautilus Biotechnolgy
NAUT
$215M
– –
-372,476
Closed -$790K
PEN icon
72
CALL
Penumbra
PEN
$12.5B
– –
-25,000
Closed -$4.74M
SNY icon
73
Sanofi
SNY
$105B
– –
-300,000
Closed -$11.4M
SNY icon
74
PUT
Sanofi
SNY
$105B
– –
-250,000
Closed -$9.51M
SPY icon
75
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$781B
– –
-250,000
Closed -$89.3M
1 2
3
4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, Affinity Asset Advisors held 89 positions worth $255M, down 29% from $358M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Affinity Asset Advisors withdrew a net $140M in Q4 2022, closing 26 positions and reducing 12 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $12.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 51% a quarter earlier, followed by Financials.

Against the trend, Affinity Asset Advisors opened a new position in BioMarin Pharmaceuticals worth $8.28M.

  • Affinity Asset Advisors's largest Q4 2022 buy was BioMarin Pharmaceuticals: 80,000 shares worth $8.28M.
  • Affinity Asset Advisors added most to Morphic Holding, Inc. Common Stock in Q4 2022, an estimated $3.67M increase.
  • Affinity Asset Advisors's biggest Q4 2022 reduction was Establishment Labs, cutting an estimated $8.21M.
  • Affinity Asset Advisors fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $12.9M.
  • Affinity Asset Advisors's ten largest holdings make up 45% of its $255M portfolio in Q4 2022.
  • Affinity Asset Advisors opened 26 new positions and closed 26 in Q4 2022.
  • Affinity Asset Advisors's portfolio value fell 29% quarter-over-quarter to $255M.

Based on Affinity Asset Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.